Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
89 studies found for:    topeka | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment
22 Recruiting Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: abiraterone;   Drug: prednisone
23 Recruiting Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
Condition: Diabetic Kidney Disease
Interventions: Drug: Finerenone (BAY94-8862);   Drug: Placebo
24 Recruiting Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Condition: Multiple Sclerosis
Interventions: Drug: Fingolimod;   Drug: other disease-modifying therapy
25 Recruiting Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Olaparib;   Drug: Placebo
26 Recruiting Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Enzalutamide;   Drug: Placebo;   Drug: Paclitaxel
27 Recruiting Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Interventions: Drug: semaglutide;   Drug: liraglutide;   Drug: placebo
28 Recruiting A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)
Condition: Ulcerative Colitis
Interventions: Drug: LT-02;   Drug: LT-02 Placebo
29 Recruiting Efficacy of Near Infrared Phototherapy in Type 2 Diabetic Neuropathy
Condition: Neuropathy
Interventions: Other: Infrared Phototherapy;   Other: Sham
30 Recruiting Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy
Condition: Crohn's Disease
Interventions: Drug: CROWN;   Drug: CROWN Placebo
31 Recruiting A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia
Condition: Alzheimer's Disease
Interventions: Drug: LY3202626;   Drug: Placebo
32 Recruiting Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study
Condition: Melanoma
33 Recruiting A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Solanezumab;   Drug: Placebo
34 Recruiting An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)
Condition: Eosinophilic Esophagitis (EoE)
Interventions: Drug: Oral Budesonide Suspension (OBS);   Drug: Placebo
35 Recruiting Long Term Safety Study of Plecanatide
Condition: Irritable Bowel Syndrome
Intervention: Drug: Plecanatide
36 Recruiting Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: ITCA 650 20/60 mcg/day;   Drug: ITCA 650 60 mcg/day
37 Recruiting Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
Conditions: Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma;   Gastric Cancer Third Line
Interventions: Drug: Avelumab;   Drug: Irinotecan;   Drug: Paclitaxel;   Other: Best Supportive Care (BSC)
38 Recruiting Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100)
Condition: Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
Interventions: Drug: Avelumab;   Drug: Oxaliplatin;   Drug: 5-Fluorouracil;   Drug: Leucovorin;   Drug: Capecitabine;   Other: Best supportive care
39 Recruiting A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Condition: Constipation Predominant Irritable Bowel Syndrome
Interventions: Drug: Tenapanor;   Drug: Placebo
40 Recruiting Vedolizumab Subcutaneous Long-Term Open-Label Extension Study
Conditions: Colitis, Ulcerative;   Crohn Disease
Intervention: Drug: Vedolizumab SC

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years